TY - JOUR
T1 - Cost-Effectiveness of Organ Donation
T2 - Evaluating Investment into Donor Action and Other Donor Initiatives
AU - Whiting, James F.
AU - Kiberd, Bryce
AU - Kalo, Zoltan
AU - Keown, Paul
AU - Roels, Leo
AU - Kierulf, Maria
PY - 2004/4
Y1 - 2004/4
N2 - Initiatives aimed at increasing organ donation can be considered health care interventions, and will compete with other health care interventions for limited resources. We have developed a model capable of calculating the cost-utility of organ donor initiatives and applied it to Donor Action, a successful international program designed to optimize donor practices. The perspective of the payer in the Canadian health care system was chosen. A Markov model was developed to estimate the net present value incremental lifetime direct medical costs and quality adjusted life years (QALYs) as a consequence of increased kidney transplantation rates. Cost-saving and cost-effectiveness thresholds were calculated. The effects of changing the success rate and time frame of the intervention was examined as a sensitivity analysis. Transplantation results in a gain of 1.99 QALYs and a cost savings of Can$104 000 over the 20-year time frame compared with waiting on dialysis. Implementation of an intervention such as Donor Action, which produced as few as three extra donors per million population, would be cost-effective at a cost of Can$ 1.0 million per million population. The cost-effectiveness of Donor Action and other organ donor initiatives compare favorably to other health care interventions. Organ donation may be underfunded in North America.
AB - Initiatives aimed at increasing organ donation can be considered health care interventions, and will compete with other health care interventions for limited resources. We have developed a model capable of calculating the cost-utility of organ donor initiatives and applied it to Donor Action, a successful international program designed to optimize donor practices. The perspective of the payer in the Canadian health care system was chosen. A Markov model was developed to estimate the net present value incremental lifetime direct medical costs and quality adjusted life years (QALYs) as a consequence of increased kidney transplantation rates. Cost-saving and cost-effectiveness thresholds were calculated. The effects of changing the success rate and time frame of the intervention was examined as a sensitivity analysis. Transplantation results in a gain of 1.99 QALYs and a cost savings of Can$104 000 over the 20-year time frame compared with waiting on dialysis. Implementation of an intervention such as Donor Action, which produced as few as three extra donors per million population, would be cost-effective at a cost of Can$ 1.0 million per million population. The cost-effectiveness of Donor Action and other organ donor initiatives compare favorably to other health care interventions. Organ donation may be underfunded in North America.
UR - http://www.scopus.com/inward/record.url?scp=1942532189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1942532189&partnerID=8YFLogxK
U2 - 10.1111/j.1600-6143.2004.00373.x
DO - 10.1111/j.1600-6143.2004.00373.x
M3 - Article
C2 - 15023149
AN - SCOPUS:1942532189
SN - 1600-6135
VL - 4
SP - 569
EP - 573
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 4
ER -